The domestic pharmaceutical sector must transition from high-volume generic formulation manufacturing to original new chemical entity discovery.
India supplies twenty percent of global generic pharmaceuticals by volume and produces over sixty percent of the world's vaccines. However, domestic firms capture less than three percent of global pharmaceutical patent value because activity is concentrated in generic formulation rather than novel molecule discovery.
Ten-year milestone: achieve at least one novel chemical entity or biologic drug approval from an Indian laboratory in the United States and Europe every year.
| Pharmaceutical metric | Current domestic baseline | Ten-year sovereign milestone |
|---|---|---|
| Patent value capture | Generic process patents (low margin) | Novel chemical entity composition of matter patents |
| Regulatory approvals (FDA / EMA) | Abbreviated new drug applications (generic) | New drug applications (NDA) for original discoveries |
| Computational drug discovery | Outsourced contract research | Indigenous ai-driven structural biology and molecular platforms |